Covid-19 roundup: Con­tro­ver­sy around colchicine per­co­lates af­ter study fail­ure; As­traZeneca's meet­ing with EU was 'con­struc­tive,' but did­n't solve much

A group of re­searchers at the Mon­tre­al Heart In­sti­tute has spelled out what they had called pos­i­tive re­sults sug­gest­ing that colchicine, an in­ex­pen­sive oral an­ti-in­flam­ma­to­ry drug com­mon­ly used to treat gout, could pre­vent Covid-19 com­pli­ca­tions in new­ly di­ag­nosed pa­tients.

The study failed its pri­ma­ry end­point. But the lat­est sci­en­tif­ic de­bate around treat­ments for the coro­n­avirus is just be­gin­ning to brew.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.